BEACON HILL WEALTH MANAGEMENT LTD.
Clone Performance
Aug 2026–Aug 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends; a captured split can shorten the simulated window. It tracks 100% of reported value on average across 1 quarter. Past performance does not predict future results.
Portfolio Concentration
7 tracked positions · as of Jun 30, 2026Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Unclassified | 95.3% | $30,327,661 |
| Technology | 4.6% | $1,461,328 |
| Healthcare | 0.1% | $22,800 |
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| DCOR |
Dimensional US Core Equity 1 ETF
|
First | 347,773 | $28,510,430 | 89.62% | |
| BNDX |
Vanguard Total International Bond ETF
|
First | 33,166 | $1,606,229 | 5.05% | |
| CINT |
CI&T Inc
Technology
|
First | 184,638 | $616,690 | 1.94% | |
| AAPL |
Apple Inc.
Technology
|
First | 1,733 | $501,460 | 1.58% | |
| MSFT |
Microsoft Corp
Technology
|
First | 920 | $343,178 | 1.08% | |
| MDY |
Spdr S&P Midcap 400 ETF Trust
|
First | 300 | $211,002 | 0.66% | |
| AKBA |
Akebia Therapeutics, Inc.
Healthcare
|
First | 20,000 | $22,800 | 0.07% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.